US Patent No: 7,700,751

Number of patents in Portfolio can not be more than 2000

Humanized antibodies that recognize β-amyloid peptide

ALSO PUBLISHED AS: 20070238154

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
JANSSEN ALZHEIMER IMMUNOTHERAPYMADISON, NJ52
WYETH LLCMADISON, NJ343

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Basi, Guriq Palo Alto, CA 25 440
Saldanha, Jose William Enfield, GB 35 371
Schenk, Dale B Pacifica, CA 154 3108

Cited Art Landscape

Patent Info (Count) # Cites Year
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (49)
6,787,523 Prevention and treatment of amyloidogenic disease 58 1998
6,761,888 Passive immunization treatment of Alzheimer's disease 68 2000
6,913,745 Passive immunization of Alzheimer's disease 48 2000
6,710,226 Transgenic mouse assay to determine the effect of A.beta. antibodies and A.beta. Fragments on alzheimer's disease characteristics 48 2000
6,743,427 Prevention and treatment of amyloidogenic disease 96 2000
6,750,324 Humanized and chimeric N-terminal amyloid beta-antibodies 53 2000
6,787,138 Prevention and treatment of amyloidogenic disease 48 2000
6,787,139 Prevention and treatment of amyloidogenic disease 46 2000
6,787,140 Prevention and treatment of amyloidogenic disease 47 2000
6,787,143 Prevention and treatment of amyloidogenic disease 40 2000
6,787,144 Prevention and treatment of amyloidogenic disease 48 2000
6,787,637 N-Terminal amyloid-.beta. antibodies 57 2000
6,875,434 Methods of treatment of Alzheimer's disease 48 2000
6,890,535 Pharmaceutical compositions and methods for treatment of amyloid diseases 41 2000
6,905,686 Active immunization for treatment of alzheimer's disease 41 2000
2004/0081,657 Prevention and treatment of amyloidogenic disease 35 2003
2005/0059,802 Prevention and treatment of amyloidogenic disease 29 2004
2004/0265,308 Prevention and treatment of amyloidogenic disease 36 2004
6,808,712 Prevention and treatment of amyloidogenic disease 29 2004
6,818,218 Prevention and treatment of amyloidogenic disease 32 2004
6,866,849 Prevention and treatment of amyloidogenic disease 47 2004
6,866,850 Prevention and treatment of amyloidogenic disease 45 2004
6,982,084 Prevention and treatment of amyloidogenic disease 26 2004
7,014,855 Prevention and treatment of amyloidogenic disease 38 2004
2005/0019,328 Prevention and treatment of amyloidogenic disease 25 2004
2005/0059,591 Prevention and treatment of amyloidogenic disease 26 2004
2004/0219,146 Prevention and treatment of amyloidogenic disease 25 2004
6,962,707 Prevention and treatment of amyloidogenic disease 34 2004
2004/0247,591 Prevention and treatment of amyloidogenic disease 19 2004
2004/0265,301 Prevention and treatment of amyloidogenic disease 20 2004
2005/0158,304 Prevention and treatment of amyloidogenic disease 19 2004
2004/0247,590 Prevention and treatment of amyloidogenic disease 20 2004
2005/0013,815 Prevention and treatment of amyloidogenic disease 28 2004
2005/0019,330 Prevention and treatment of amyloidogenic disease 47 2004
2005/0048,049 Prevention and treatment of amyloidogenic disease 25 2004
2005/0191,292 Prevention and treatment of amyloidogenic disease 19 2004
2005/0249,727 Prevention and treatment of amyloidogenic disease 26 2004
2005/0196,399 Prevention and treatment of amyloidogenic disease 20 2004
2005/0163,788 Prevention and treatment of amyloidogenic disease 26 2004
2005/0255,122 Prevention and treatment of amyloidogenic disease 26 2004
6,946,135 Prevention and treatment of amyloidogenic disease 34 2004
6,972,127 Prevention and treatment of amyloidogenic disease 45 2004
2005/0142,132 Prevention and treatment of amyloidogenic disease 27 2005
2005/0191,314 Prevention and treatment of amyloidogenic disease 27 2005
2006/0029,611 Prevention and treatment of amyloidogenic disease 24 2005
2006/0034,858 Prevention and treatment of amyloidogenic disease 24 2005
2007/0154,480 Humanized antibodies that recognize beta amyloid peptide 25 2006
2008/0096,818 PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE 25 2007
2009/0069,544 HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE 11 2007
 
WYETH LLC (25)
7,189,819 Humanized antibodies that recognize beta amyloid peptide 32 2001
2005/0009,150 Humanized antibodies that recognize beta amyloid peptide 21 2002
7,179,892 Humanized antibodies that recognize beta amyloid peptide 45 2003
7,256,273 Humanized antibodies that recognize beta amyloid peptide 40 2003
2004/0171,815 Humanized antibodies that recognize beta amyloid peptide 31 2003
2004/0171,816 Humanized antibodies that recognize beta amyloid peptide 25 2003
2006/0188,512 Active immunization to generate antibodies to solble a-beta 18 2004
2004/0213,800 Active immunization to generate antibodies to soluble A-beta 26 2004
2005/0249,725 Humanized antibodies that recognize beta amyloid peptide 29 2004
2005/0118,651 Humanized antibodies that recognize beta amyloid peptide 34 2004
2007/0134,762 Immunogenic peptide carrier conjugates and methods of producing same 23 2004
2007/0161,088 Beta immunogenic peptide carrier conjugates and methods of producing same 23 2004
2006/0160,161 Methods for assessing antibodies to neurodegenerative disease-associated antigens 25 2005
2006/0153,772 Contextual fear conditioning for predicting immunotherapeutic efficacy 18 2005
2006/0165,682 Humanized antibodies that recognize beta amyloid peptide 23 2005
2006/0198,851 Humanized Abeta antibodies for use in improving cognition 30 2005
2006/0240,486 Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies 23 2005
2006/0257,396 Abeta antibodies for use in improving cognition 30 2005
2006/0193,850 Anti a beta antibody formulation 30 2006
2006/0280,743 Humanized antibodies that recognize beta amyloid peptide 28 2006
2007/0082,367 Methods of purifying anti a beta antibodies 21 2006
2008/0050,367 Humanized antibodies that recognize beta amyloid peptide 20 2006
2007/0238,154 Humanized antibodies that recognize beta-amyloid peptide 20 2007
2008/0145,373 A-BETA IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME 21 2007
2009/0142,270 PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY 16 2008
 
Genentech, Inc. (13)
4,816,567 Recombinant immunoglobin preparations 1605 1983
5,245,015 Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro 27 1991
5,866,129 Method of producing an antibody with a peptide corresponding to membrane-bound IgA 26 1991
6,407,213 Method for making humanized antibodies 205 1993
5,869,046 Altered polypeptides with increased half-life 87 1995
6,121,022 Altered polypeptides with increased half-life 102 1995
6,054,297 Humanized antibodies and methods for making them 272 1995
5,702,906 Antibodies to neurotrophic factor-4 (NT-4) 26 1995
6,267,958 Protein formulation 155 1996
6,194,551 Polypeptide variants 170 1999
6,528,624 Polypeptide variants 152 1999
6,538,124 Polypeptide variants 130 2000
6,639,055 Method for making humanized antibodies 91 2000
 
Eli Lilly and Company (10)
5,441,870 Methods for monitoring cellular processing of .beta.-amyloid precursor protein 121 1992
5,766,846 Methods of screening for compounds which inhibit soluble .beta.-amyloid peptide production 127 1993
5,612,486 Transgenic animals harboring APP allele having swedish mutation 134 1993
6,114,133 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreq.41) 86 1994
5,624,937 Chemical compounds as inhibitors of amyloid beta protein production 67 1995
5,593,846 Methods for the detection of soluble .beta.-amyloid peptide 201 1995
5,605,811 Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein 76 1995
5,721,130 Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of .beta.APP 90 1995
5,837,672 Methods and compositions for the detection of soluble .beta.-amyloid peptide 106 1995
6,284,221 Method for identifying .beta.-amyloid peptide production inhibitors 68 1996
 
BRONSON NUTRITIONALS, LLC (5)
5,869,093 Treatment of immune diseases by oral administration of autoantigens 62 1994
5,645,820 Treatment of autoimmune diseases by aerosol administration of autoantigens 59 1995
5,571,499 Treatment of autoimmune diseases by aerosol administration of autoantigens 73 1995
5,571,500 Treatment of autoimmune diseases through administration by inhalation of autoantigens 60 1995
5,641,474 Prevention of autoimmune diseases by aerosol administration of autoantigens 57 1995
 
GENETICS INSTITUTE, LLC (5)
5,385,887 Formulations for delivery of osteogenic proteins 146 1993
6,270,757 Formulations for IL-11 24 1994
6,372,716 Formulations for factor IX 22 1994
5,770,700 Liquid factor IX formulations 44 1996
5,744,132 Formulations for IL-12 31 1997
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (5)
4,912,206 CDNA clone encoding brain amyloid of alzheimer's disease 37 1987
5,472,693 Family of anti-carcinoembryonic antigen chimeric antibodies 33 1993
5,733,548 Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments 30 1995
2003/0068,316 Anti-ADDL antibodies and uses thereof 56 2002
2003/0166,557 SEMA3B inhibits tumor growth and induces apoptosis in cancer cells 20 2002
 
PROTEIN DESIGN LABS, INC. (5)
5,530,101 Humanized immunoglobulins 785 1990
5,585,089 Humanized immunoglobulins 811 1995
5,693,761 Polynucleotides encoding improved humanized immunoglobulins 348 1995
5,693,762 Humanized immunoglobulins 634 1995
6,180,370 Humanized immunoglobulins and methods of making the same 405 1995
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (5)
4,666,829 Polypeptide marker for Alzheimer's disease and its use for diagnosis 251 1985
5,270,165 Method of diagnosis of amyloidoses 75 1991
5,464,823 Mammalian antibiotic peptides 61 1993
5,750,361 Formation and use of prion protein (PRP) complexes 62 1995
6,175,057 Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy 33 1997
 
AUTOIMMUNE, INC. (4)
5,849,298 Treatment of multiple sclerosis by oral administration of bovine myelin 48 1993
5,869,054 Treatment of multiple sclerosis by oral administration of autoantigens 53 1995
5,733,547 Treatment of autoimmune arthritis by oral administration of type I or type III collagen 51 1995
5,641,473 Treatment of autoimmune diseases by aerosol administration of autoantigens 51 1995
 
MILKHAUS LABORATORY, INC. (4)
5,753,624 Materials and methods for treatment of plaquing disease 81 1996
5,798,102 Treatment of cardiomyopathy 23 1997
5,851,996 Materials and methods for treatment of plaquing diseases 86 1998
6,294,171 Methods for treating disease states comprising administration of low levels of antibodies 63 2001
 
BOSTON BIOMEDICAL RESEARCH INSTITUTE (3)
6,582,945 Immunological control of .beta.-amyloid levels in vivo 47 2000
2002/0136,718 Immunological control of beta-amyloid levels in vivo 60 2001
2005/0147,613 Immunological control of beta-amyloid levels in vivo 25 2005
 
GLAXOSMITHKLINE LLC (3)
5,817,626 Modulators of beta-amyloid peptide aggregation 67 1995
5,854,215 Modulators of .beta.-amyloid peptide aggregation 57 1995
5,854,204 A.beta. peptides that modulate .beta.-amyloid aggregation 101 1996
 
PRAECIS PHARMACEUTICALS INCORPORATED (3)
6,303,567 Modulators of .beta.-amyloid peptide aggregation comprising D-amino acids 69 1996
5,985,242 Modulators of .beta.-amyloid peptide aggregation comprising D-amino acids 57 1997
2002/0133,001 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease 42 2001
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (3)
5,837,473 Methods of screening for agents affecting the deposition of .beta.-amyloid peptides on amyloid plaques in human tissue 50 1995
5,877,399 Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease 115 1996
6,262,335 Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 53 1998
 
SCIOS NOVA INC. (3)
5,220,013 DNA sequence useful for the detection of Alzheimer's disease 69 1989
5,187,153 Methods of treatment using Alzheimer's amyloid polypeptide derivatives 74 1990
5,387,742 Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease 187 1991
 
The Scripps Research Institute (3)
4,879,213 Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse 199 1986
5,846,533 Antibodies specific for native PrP.sup.Sc 73 1996
6,562,341 Antibodies specific for native PrPSc 32 2001
 
ANTIGENICS INC. (2)
5,057,540 Saponin adjuvant 170 1990
5,583,112 Saponin-antigen conjugates and the use thereof 87 1992
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (2)
6,165,745 Recombinant production of immunoglobulin-like domains in prokaryotic cells 143 1994
6,277,375 Immunoglobulin-like domains with increased half-lives 200 1997
 
CELLTECH R&D LIMITED (2)
5,859,205 Humanised antibodies 269 1994
6,632,927 Humanized antibodies 179 2001
 
CITY OF HOPE (2)
5,652,334 Method for design of substances that enhance memory and improve the quality of life 27 1993
5,470,951 Peptides for antagonizing the effects of amyloid .beta.protein 41 1993
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2)
4,883,666 Controlled drug delivery system for treatment of neural disorders 202 1987
5,891,991 Amyloid precursor-like protein and uses thereof 33 1996
 
NEUROCHEM (INTERNATIONAL) LIMITED (2)
6,331,440 Peptide binding the KLVFF-sequence of amyloid-.beta. 34 1998
2002/0094,335 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases 63 2001
 
NEW YORK UNIVERSITY (2)
6,713,450 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits 36 2001
2003/0166,558 Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or polyglutamine repeats for induction of an immune response thereto 46 2002
 
RAMOT AT TEL-AVIV UNIVERSITY LTD. (2)
5,688,651 Prevention of protein aggregation 88 1994
2005/0152,878 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases 20 2005
 
SB2, INC. (2)
5,624,821 Antibodies with altered effector functions 291 1995
5,648,260 DNA encoding antibodies with altered effector functions 233 1995
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (2)
5,750,349 Antibodies to .beta.-amyloids or their derivatives and use thereof 117 1994
5,955,317 Antibodies to .beta.-amyloids or their derivatives and use thereof 79 1997
 
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (2)
5,585,100 Dual carrier immunogenic construct 70 1995
5,955,079 Dual carrier immunogenic construct 57 1995
 
UCB PHARMA S.A. (2)
2005/0123,534 Humanised antibodies 21 2004
2005/0136,054 Humanised antibodies 20 2004
 
UNIVERSITY OF WASHINGTON (2)
5,958,883 Animal models of human amyloidoses 75 1995
7,195,761 Humanized antibodies that sequester abeta peptide 37 2002
 
WYETH (2)
2006/0099,206 Methods and compositions for improving recombinant protein production 21 2005
2006/0210,557 Stabilized liquid polypeptide formulations 26 2006
 
WYETH HOLDINGS CORPORATION (2)
5,723,130 Adjuvants for vaccines against respiratory syncytial virus 39 1996
6,399,314 Methods of detection of amyloidogenic proteins 50 1999
 
XOMA TECHNOLOGY LTD. (2)
5,618,920 Modular assembly of antibody genes, antibodies prepared thereby and use 129 1994
5,576,184 Production of chimeric mouse-human antibodies with specificity to human tumor antigens 103 1994
 
ABBOTT BIOTHERAPEUTICS CORP. (1)
6,210,671 Humanized antibodies reactive with L-selectin 56 1995
 
ABBOTT LABORATORIES (1)
6,015,662 Reagents for use as calibrators and controls 30 1996
 
ABBVIE BIOTHERAPEUTICS INC. (1)
5,622,701 Cross-reacting monoclonal antibodies specific for E- and P-selectin 59 1994
 
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (1)
2006/0182,321 Method and apparatus for extracting third ventricle information 17 2004
 
ALTEON, INC. (1)
5,935,927 Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts 73 1996
 
AMERSHAM PLC (1)
2003/0135,035 Human ZZAP1 protein 18 2002
 
AMGEN INC. (1)
5,731,284 Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product 27 1995
 
ANDRULIS PHARMACEUTICALS CORPORATION (1)
5,434,170 Method for treating neurocognitive disorders 86 1993
 
AVANT IMMUNOTHERAPEUTICS, INC. (1)
6,284,533 Plasmid-based vaccine for treating atherosclerosis 45 1998
 
BAYER CORPORATION (1)
2002/0160,394 Regulation of transthyretin to treat obesity 53 2002
 
BAYER PHARMACEUTICALS CORPORATION (1)
5,786,180 Monoclonal antibody 369.2B specific for .beta. A4 peptide 67 1995
 
BIOCLONES (PROPRIETARY) LIMITED (1)
6,261,569 Retro-, inverso- and retro-inverso synthetic peptide analogues 56 1997
 
BIOSITE INCORPORATED (1)
6,057,098 Polyvalent display libraries 89 1997
 
BRITISH TECHNOLOGY GROUP LIMITED (1)
5,096,706 Antigen-based treatment for adiposity 24 1986
 
BTG INTERNATIONAL LIMITED (1)
6,548,640 Altered antibodies 100 1995
 
CEDARS-SINAI MEDICAL CENTER (1)
5,679,348 Immunotherapy for recurrent HSV infections 48 1992
 
CELLTECH LIMITED (1)
4,816,397 Multichain polypeptides or proteins and processes for their production 498 1984
 
CELLTECH THERAPEUTICS LIMITED (1)
5,677,425 Recombinant antibody 78 1994
 
CREATIVE BIOMOLECULES, INC. (1)
5,258,498 Polypeptide linkers for production of biosynthetic proteins 208 1992
 
CYTRX CORPORATION (1)
5,824,322 Compositions and methods for growth promotion 52 1996
 
DMS PHARMACEUTICAL INC. (1)
5,231,170 Antibodies to dense microspheres 72 1990
 
ELAN PHARMACEUTICALS, INC. (1)
6,610,493 Screening compounds for the ability to alter the production of amyloid-.beta. peptide 30 1996
 
EPIMMUNE INC. (1)
5,736,142 Alteration of immune response using pan DR-binding peptides 72 1994
 
GLAXOSMITHKLINE BIOLOGICALS S.A. (1)
5,776,468 Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A 75 1996
 
HUNTINGTON POTTER (1)
5,780,587 Compounds and methods for inhibiting .beta.-protein filament formation and neurotoxicity 73 1995
 
IMMUNITOR COMPANY LTD. (1)
2003/0092,145 Viral vaccine composition, process, and methods of use 30 2001
 
INNOGENETICS N.V. (1)
2004/0265,919 Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease 28 2004
 
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (1)
6,150,091 Direct molecular diagnosis of Friedreich ataxia 50 1996
 
INTELLECT NEUROSCIENCES INC. (1)
2003/0073,655 Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof 59 2002
 
ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (1)
5,994,083 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable 21 1995
 
LILLY AND COMPANY (1)
2004/0241,164 Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass 40 2004
 
MCW RESEARCH FOUNDATION, INC. (1)
6,057,367 Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses 76 1997
 
MEDICAL RESEARCH COUNCIL (1)
5,225,539 Recombinant altered antibodies and methods of making altered antibodies 572 1991
 
MEMORIAL SLOAN-KETTERING CANCER CENTER (1)
6,933,368 Increasing antibody affinity by altering glycosylation of immunoglobulin variable region 54 2002
 
MERCK SHARP & DOHME CORP. (1)
5,358,708 Stabilization of protein formulations 57 1993
 
MILLENNIUM PHARMACEUTICALS, INC. (1)
6,727,349 Recombinant anti-CCR2 antibodies and methods of use therefor 22 2000
 
Mindset Biopharmaceuticals (USA) (1)
2002/0086,847 Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof 68 2001
 
MORPHOSYS AG (1)
2005/0169,925 Anti-amyloid beta antibodies and their use 33 2005
 
Morphosys Gesellschaft fur Proteinoptimerung mbH (1)
5,514,548 Method for in vivo selection of ligand-binding proteins 85 1994
 
NATIONAL RESEARCH COUNCIL OF CANADA (1)
5,773,007 Vaccine compositions 26 1994
 
NEOTOPE BIOSCIENCES LIMITED (1)
6,923,964 Active immunization of AScr for prion disorders 32 2000
 
NEURALAB LIMITED (1)
2005/0123,544 Prevention and treatment of amyloidogenic disease 29 2004
 
New York Blood Center, Inc. (1)
5,620,844 Assays for detecting hepatitis B virus envelope antigens or antibodies thereto and diagnostic test kits for use in performing the assays 19 1993
 
NIHON UNIVERSITY (1)
6,962,984 IgA nephropathy-related DNA 18 2000
 
NOVARTIS AG (1)
2004/0197,324 High concentration antibody and protein formulations 58 2004
 
PARDRIDGE, WILLIAM (1)
5,004,697 Cationized antibodies for delivery through the blood-brain barrier 83 1987
 
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (1)
5,601,827 Diphtheria toxin vaccines 32 1995
 
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (1)
5,589,154 Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease 69 1994
 
SMITHKLINE BEECHAM CORPORATION (1)
6,936,698 Monoclonal antibodies with reduced immunogenicity 24 2001
 
SUN HEALTH CORPORATION, INC. (1)
5,192,753 Anti-rheumatoid arthritic drugs in the treatment of dementia 85 1991
 
Syntex (U.S.A.) Inc. (1)
5,208,036 N-(.omega., (.omega.-1)-dialkyloxy)- and N-(.omega., (.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor 125 1990
 
T C U.S.A. INC. (1)
6,787,129 Castor polyester as gloss agents in anionic systems 15 2003
 
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (1)
5,262,332 Diagnostic method for Alzheimer's disease: examination of non-neural tissue 53 1989
 
THE GENERAL HOSPITAL CORPORATION (1)
2003/0009,104 In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease 12 2001
 
THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (1)
4,713,366 Antigenic modification of polypeptides 72 1985
 
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (1)
5,744,368 Methods for the detection of soluble amyloid .beta.-protein (.beta.AP) or soluble transthyretin (TTR) 60 1993
 
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (1)
5,858,981 Method of inhibiting phagocytosis 37 1996
 
THE UNIVERSITY OF BRITISH COLUMBIA (1)
2006/0234,912 Methods for modulating neuronal responses 13 2006
 
UNIVERSITY OF IOWA RESEARCH FOUNDATION (1)
6,339,068 Vectors and methods for immunization or therapeutic protocols 164 1998
 
UNIVERSITY OF KANSAS (1)
5,278,049 Recombinant molecule encoding human protease nexin 37 1987
 
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
6,417,178 Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits 72 1997
 
UNIVERSITY OF ROCHESTER (1)
5,231,000 Antibodies to A4 amyloid peptide 106 1991
 
UNIVERSITY OF SASKATCHEWAN (1)
5,837,268 GnRH-leukotoxin chimeras 26 1996
 
UNIVERSITY OF SOUTHERN CALIFORNIA (1)
6,218,506 Amyloid .beta. protein (globular assembly and uses thereof) 65 1997
 
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (1)
2003/0147,882 METHODS FOR AMYLOID REMOVAL USING ANTI-AMYLOID ANTIBODIES 39 1999
 
WISCONSIN ALUMNI RESEARCH FOUNDATION (1)
6,022,859 Inhibitors of .beta.-amyloid toxicity 29 1997
 
ZOETIS WHC 2 LLC (1)
5,989,566 Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation 50 1996
 
Other [Check patent profile for assignment information] (4)
5,227,159 Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies 29 1992
2002/0009,445 Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease 78 2001
2002/0197,258 Compositions and methods for preventing protein aggregation in neurodegenerative diseases 70 2002
2004/0247,612 Immunogenic peptide composition for the prevention and treatment of Alzheimer's Disease 23 2004

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
NATIONAL CHENG KUNG UNIVERSITY (1)
8,597,647 Humanized anti-IL-20 antibody and uses thereof 0 2012
 
WYETH LLC (1)
8,440,799 Methods of purifying anti A β antibodies 0 2010

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 20, 2017
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 20, 2021
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00